SummitTherapeutics (SMMT) partner Akeso reported "positive" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer, Summit Therapeutics said late Tuesday.
The ivonescimab-based regimen showed "statistically significant and clinically meaningful superiority" in the study's primary endpoint of overall survival, compared with the durvalumab-based regimen, the company said.
The trial, conducted in China, also met its secondary endpoints of progression-free survival and objective response rate, according to Summit Therapeutics.
The company's shares were up 4.5% in premarket activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.